Literature DB >> 8787951

New reliable biochemical marker for screening 21 alpha-hydroxylase deficiency without index person among hirsute women in agreement with HLA-haplotyping.

A Chryssikopoulos1, I Phocas, A Sarandakou, E Trakakis, D Rizos.   

Abstract

Late onset congenital adrenal hyperplasia due to 21 alpha-hydroxylase deficiency (LO21OH def), as many other diseases, is the cause of hirsutism, menstrual disorders, infertility (PCO-like symptoms). We evaluated the reliability of a new biochemical marker for screening LO-21OH def in 47 women with PCO-like symptoms and 11 men, members of their families, comparing the results of separation using this new marker with those of HLA-haplotyping in 21 members of the patient population. All subjects were stimulated with 0.25 mg synthetic ACTH iv. Serum progesterone (P), 17-hydroxyprogesterone (17-OHP) and cortisol (F) at 0, 15, 30, 45 and 60 min following ACTH administration were determined and the new marker, namely the difference between 60min and 0min of the ratio F/17-OHP [delta F/17-OHP (60 min -0 min)] was calculated. According to the established biochemical criteria for the detection of LO-21OH def cases, (Gutai 30 min > or = 12 ng/dl/min and 17-OHP 60 min > or = 12 ng/ml for severe 21-OH def and Gutai 30 min < 6.5 ng/dl/min and 17-OHP 60 min < 5 ng/ml for "healthy" individuals regarding 21-OH def) two groups, A and B respectively, were separated from the patient population. In group A (n = 8), with LO-21OH def, the new marker showed negative values in all cases, while in group B (n = 9), without LO-21OH def, this marker was positive. The remaining subjects, depending on the results of the new marker were separated in 2 subgroups, Cneg (n = 28), with negative values, composed, consequently, of members with 21-OH def and Cpos (n = 13), with positive values, composed, consequently, of subjects with absence of LO-21OH def. HLA-typing was in agreement with the results of screening by the new marker, in 20 out of 21 cases, while there was only one false negative result. In conclusion, the proposed biochemical marker delta F/17-OHP (60 min-0 min) seems to be a reliable parameter for the LO-21OH def detection among young women with PCO-like symptoms as well as males suspected for congenital adrenal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8787951     DOI: 10.1007/bf03349807

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  36 in total

1.  HLADR5 and C4BQO high frequency and antinuclear antibodies positivity in patients with 21 hydroxylase deficiency from Campania region.

Authors:  F Parlato; G Pisano; G Misiano; E Cosentini; C Cacciapuoti; M R Cavalcanti; M Brai; A Bellastella
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

2.  [A genetic and hormonal study of 5 patients with the nonclassical form of congenital adrenal hyperplasia due to 21-hydroxylase deficiency].

Authors:  F J Velasco; A M Picó; C Muñoz; M Mauri; M L de la Sen
Journal:  Med Clin (Barc)       Date:  1992-06-13       Impact factor: 1.725

3.  High frequency of nonclassical steroid 21-hydroxylase deficiency.

Authors:  P W Speiser; B Dupont; P Rubinstein; A Piazza; A Kastelan; M I New
Journal:  Am J Hum Genet       Date:  1985-07       Impact factor: 11.025

Review 4.  Late onset congenital adrenal hyperplasia: a gynecologist's perspective.

Authors:  B L Brodie; A C Wentz
Journal:  Fertil Steril       Date:  1987-08       Impact factor: 7.329

5.  Cryptic 21-hydroxylase deficiency in families of patients with classical congenital adrenal hyperplasia.

Authors:  L S Levine; B Dupont; F Lorenzen; S Pang; M Pollack; S Oberfield; B Kohn; A Lerner; E Cacciari; F Mantero; A Cassio; C Scaroni; G Chiumello; G F Rondanini; L Gargantini; G Giovannelli; R Virdis; E Bartolotta; C Migliori; C Pintor; L Tato; F Barboni; M I New
Journal:  J Clin Endocrinol Metab       Date:  1980-12       Impact factor: 5.958

6.  Is heterozygosity for the steroid 21-hydroxylase deficiency responsible for hirsutism, premature pubarche, early puberty, and precocious puberty in children?

Authors:  D Knorr; F Bidlingmaier; W Höller; U Kuhnle; B Meiler; A Nachmann
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1986

7.  Genotype and hormonal phenotype in nonclassical 21-hydroxylase deficiency.

Authors:  P W Speiser; M I New
Journal:  J Clin Endocrinol Metab       Date:  1987-01       Impact factor: 5.958

8.  Prevalence of and markers for the attenuated form of congenital adrenal hyperplasia and hyperprolactinemia masquerading as polycystic ovarian disease.

Authors:  F Benjamin; S Deutsch; H Saperstein; V L Seltzer
Journal:  Fertil Steril       Date:  1986-08       Impact factor: 7.329

Review 9.  Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome.

Authors:  R L Rosenfield; R B Barnes; J F Cara; A W Lucky
Journal:  Fertil Steril       Date:  1990-05       Impact factor: 7.329

10.  The endocrine pattern of late onset adrenal hyperplasia (21-hydroxylase deficiency).

Authors:  E Carmina; A M Gagliano; F Rosato; M Maggiore; A Jannì
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.